Elan

Action brought by drug firm against Revenue closely watched for implications beyond case

US pharma giant says it is disappointed by High Court judgment

Group eyeing up to 10 investments, mostly in therapeutics and medical device sectors

Judgment could have major implications well beyond the drug company

Company says third quarter saw drop in revenue as restrictions hit business

Drug company not being ‘singled out’ in dispute over tax assessment, High Court told

Tax collector maintains Perrigo owes the money because of its 2013 purchase of Elan

Pharma group challenging ‘surprise’ Revenue assessment in hearing via video link

US drug company case to be heard via video link due to Covid-19 courtroom restrictions

Irish tax authorities argue sale of drug for MS should have been treated as capital gain

US analyst RBC upbeat about High Court challenge to €1.64bn charge over Tysabri

Legalisation is coming, no matter what Irish policymakers may say now

Tax bill linked to sale by Elan of its stake in multiple sclerosis drug Tysabri in 2013

Perrigo has repeatedly argued it will defend its position in the tax case, and denies Elan underpaid tax on the Tysabri deal

Revenue should not have issued notice of amended assessment of liability, firm says

Theratechnologies has appointed Conor Walshe to the role of general manager

Peter Chambré and Shane Cooke to take up roles with services provider on February 1st

Pharma group understood to have filed documents to contest assessment

Listed pharmaceutical giant has signalled its intention to appeal Revenue’s tax assessment

Cliff Taylor: Contrasting approaches to tax bills show the delicate balance Ireland must strike

Company confirmed it faces Revenue demand for €1.64bn in back taxes

Revenue’s activist approach has not gone unnoticed

Cliff Taylor answers all your questions

Losses must be declared for Revenue to track them if they are being offset against gains

Entrepreneur might turn attention to Maynooth University cancer therapy spinout

New €20m six-storey block in Dublin 2 has parking for 40 cars and 56 bicycle spaces

Aisling Quirke’s entrepreneurial instinct found a natural home among fintech opportunities in Africa

Varadkar backs Minister’s consent granted to O’Brien to take up board role at US firm

Food and Drug Administration accepts filing from Irish pharma group fortnight after refusal

Martin will juggle his time between Malin and Novan

Irish-domiciled biopharma group reported 31% rise in sales last year

Failed drug trials have led some scientists and Big Pharma executives to doubt the central theory behind its cause

CEO John Hendrickson says drug faces increased competition and potential for wider use has failed to materialise

‘I’m conscious of supporting independent business, they are the backbone of the economy’

Irish-listed Malin to take a 31 per cent stake in US-based human therapeutics firm

CEO Joe Papa and CFOJudy Brown hope to persuade Israeli holders of 10% of company not to accept takeover offer

Company reported its loss and revenue from investments at €2.5m in maiden set of results

Irish pharma company claims Mylan’s $27bn offer overstates potential synergies and makes false claims

The company looking to buy Perrigo has a stated policy of not paying dividends

Irish life sciences investment firm completes initial series of asset purchases